



ANDA 091216

Teva Pharmaceuticals USA  
U.S. Agent for: GATE Pharmaceuticals  
Attention: Deborah A. Jaskot  
Vice President, North American, Regulatory Affairs  
1090 Horsham Road  
P.O. Box 1090  
North Wales, PA 19454

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 29, 2008, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Clopidogrel Tablets USP, 300 mg.

Reference is also made to your amendments dated April 27, May 5, October 29, and November 5, 2010; October 13, 2011; and January 23, March 21, and April 20, 2012.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Clopidogrel Tablets USP, 300 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Plavix Tablets, 300 mg, of Sanofi Aventis U.S. LLC (Sanofi). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your ANDA.

The RLD upon which you have based your ANDA, Sanofi's Plavix Tablets, 300 mg, is subject to periods of patent protection. As noted in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"), U.S. Patent Nos. 6,429,210 (the '210 patent) and 6,504,030 (the '030 patent) expire on December 10, 2019 (with pediatric exclusivity added).

It is noted that these patents were listed after submission of your ANDA. Litigation, if any, with respect to these patents will therefore not delay approval of your ANDA. It is also noted that these patents were submitted for listing late and therefore you were not required to submit an amended certification with respect to them. See 21 CFR 314.94(a)(12)(vi).

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLab>

[eling/default.htm](#), that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

*{See appended electronic signature page}*

Keith Webber, Ph.D.  
Deputy Director  
Office of Pharmaceutical Science  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

ROBERT L WEST

05/17/2012

Deputy Director, Office of Generic Drugs  
for Keith Webber, Ph.D.